NAALADL2 and prostate cancer: Here we utilise large-scale publicly available genomic data to better characterise the broad somatic copy-number changes occurring within the 3q26.31-32 locus, particularly centred around gains/amplifications in NAALADL2 and TBL1XR1 and linking them to the clinical characteristics of aggressive prostate cancer.